Development of Validated Stability Indicating HPTLC Method for the Estimation of Teriflunomide in Bulk and Tablet Dosage Form

Teriflunomide is an immunosuppressive agent. Immunosuppressive agents are drugs that inhibit or prevent activity of immune system. Teriflunomide was investigated as a medication for multiple sclerosis (MS). Various studies have reported the HPLC, UPLC, LC/MS methods for the estimation of teriflunomide. However, till date stability indicating HPTLC analysis method has not been reported for the estimation of teriflunomide in bulk and tablet dosage form. Objective of the present work was to develop and validate stability indicating high performance thin layer chromatography method for the determination of teriflunomide in bulk and tablet dosage form. Chromatography was performed on aluminium plates coated with silica gel 60F254 using toluene, methanol and acetic acid (7.5: 2.5: 0.05 v/v/v) as mobile phase. Densitometric analysis was performed at 254 nm. The method was validated with different parameters such as linearity, precision, accuracy, specificity, robustness, limit of detection (LOD) and limit of quantitation (LOQ). The RF value of teriflunomide was 0.56 ± 0.03. The method is sensitive (limit of quantification 17.83 ng/band), precise (RSD ≤ 1.34%), accurate (drug recovery 98.49–99.53 %), and linear over the range 100–600 ng/band (r2 0.998). Degradation products were found in stress conditions did not interfere with the detection of teriflunomide; therefore, the proposed technique can be considered stability-indicating. Teriflunomide did not degrade under alkaline hydrolysis, thermal and photolytic conditions but showed degradation under acid hydrolysis and oxidation with about 14.5 and 13.8 % decompositions respectively. The developed method was satisfactorily applied for the analysis of pharmaceutical preparations and proved to be specific and accurate for quality control of the cited drugs in their tablet dosage form.

[1]  Sarfaraz K. Niazi Stability Testing: Photostability Testing of New Drug Substances and Products , 2019, Handbook of Pharmaceutical Manufacturing Formulations.

[2]  Nukendra Prasad Nadella,et al.  Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in-vitro dissolution , 2017 .

[3]  Sarfaraz Niazi,et al.  Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products , 2016, Handbook of Pharmaceutical Manufacturing Formulations, Second Edition.

[4]  P. Riccio,et al.  Nutrition Facts in Multiple Sclerosis , 2015, ASN neuro.

[5]  B. Saini,et al.  Isolation and characterization of a degradation product in leflunomide and a validated selective stability-indicating HPLC–UV method for their quantification , 2014, Journal of pharmaceutical analysis.

[6]  M. Freedman Teriflunomide in relapsing multiple sclerosis: therapeutic utility , 2013, Therapeutic advances in chronic disease.

[7]  T. Rozek,et al.  Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. , 2011, Journal of pharmaceutical and biomedical analysis.

[8]  J. Marriott,et al.  Emerging therapies in relapsing-remitting multiple sclerosis. , 2010, Reviews on recent clinical trials.

[9]  P. Shrivastav,et al.  Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[10]  H. Hartung,et al.  Review of teriflunomide and its potential in the treatment of multiple sclerosis , 2009, Neuropsychiatric disease and treatment.